☆ 4.7 Meeting Abstract

Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas

JOURNAL OF CLINICAL ONCOLOGY (2014)

期刊

JOURNAL OF CLINICAL ONCOLOGY

卷 32, 期 3, 页码 -

出版社

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/jco.2014.32.3_suppl.178

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Letter Oncology

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study

Shuling Chen, Jiaxin Li, Aoran Dong, Zelong Liu, Meiyan Zhu, Meng Jin, Guangyan Wei, Shuang Wu, Yan Wang, Yong Chen, Zhenwei Peng

Summary: This study compared the efficacy and safety of combination therapy with immunotherapy and radiotherapy versus chemotherapy alone for patients with locally advanced pancreatic adenocarcinoma (LAPC). The combination treatment group showed significant advantages in median overall survival and progression-free survival compared to the chemotherapy alone group. However, the incidence of severe adverse events did not differ significantly between the two groups. Therefore, combination therapy appears to be an effective and safe treatment option for LAPC patients.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Gemcitabine plus Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study

Simon Zaibet, Vincent Hautefeuille, Edouard Auclin, Astrid Lievre, David Tougeron, Mathieu Sarabi, Marine Gilabert, Julie Wasselin, Julien Edeline, Pascal Artru, Dominique Bechade, Clemence Morin, Agnes Ducoulombier, Julien Taieb, Simon Pernot

Summary: This study evaluates the efficacy and safety of adding Nab-paclitaxel to Gem for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX failure. The results show that Gem-Nab is associated with better disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) compared with Gem alone, but with higher toxicity.

BRITISH JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study

Yuan Zong, Jiajia Yuan, Zhi Peng, Ming Lu, Xicheng Wang, Lin Shen, Jun Zhou

Summary: The study compared the efficacy and safety of nab-paclitaxel plus S-1 with nab-paclitaxel plus gemcitabine in first-line chemotherapy for patients with PDAC. Despite comparable efficacy, the nab-P/S combination showed improved safety profile with reduced risks of hematological toxicity, liver injury, and rash. There were no significant differences in primary and secondary endpoints between the two treatment arms.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Avital Klein-Brill, Shlomit Amar-Farkash, Gabriella Lawrence, Eric A. Collisson, Dvir Aran

Summary: This study compared the two common first-line treatments for metastatic adenocarcinoma of the pancreas, FOLFIRINOX and gemcitabine plus nab-paclitaxel, and found that FOLFIRINOX was associated with improved overall survival and fewer posttreatment complications.

JAMA NETWORK OPEN (2022)

添加到收藏夹

Article Oncology

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer

Satoshi Kobayashi, Motoko Suzuki, Makoto Ueno, Yuta Maruki, Naohiro Okano, Akiko Todaka, Masato Ozaka, Kunihiro Tsuji, Kazuhiko Shioji, Keitaro Doi, Yasushi Kojima, Hidetaka Tsumura, Kazunari Tanaka, Hajime Higuchi, Ken Kawabe, Hiroshi Imaoka, Tatsuya Yamashita, Haruo Miwa, Hiroaki Nagano, Shiho Arima, Hideyuki Hayashi, Atsushi Naganuma, Hironori Yamaguchi, Terumasa Hisano, Kumiko Umemoto, Shuji Ishii, Koji Nakashima, Rei Suzuki, Yohei Kitano, Toshihiro Misumi, Junji Furuse, Hiroshi Ishii

Summary: This study investigated the efficacy and safety of Gemcitabine plus nab-paclitaxel (GnP) compared to other treatments in older adults with unresectable pancreatic cancer (uPC). The results showed that GnP was more effective than Gem in patients aged 76 years and older, despite a higher incidence of severe adverse events.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma

Patrick M. Grierson, Benjamin Tan, Katrina S. Pedersen, Haeseong Park, Rama Suresh, Manik A. Amin, Nikolaos A. Trikalinos, Deborah Knoerzer, Brent Kreider, Anupama Reddy, Jingxia Liu, Channing J. Der, Andrea Wang-Gillam, Kian-Huat Lim

Summary: This study evaluated the efficacy and safety of ulixertinib combined with gemcitabine and nab-paclitaxel (GnP) for untreated metastatic pancreatic adenocarcinoma. The results showed that ulixertinib plus GnP had similar toxicity and efficacy as GnP, but was complicated by a high rate of all-grade treatment-related adverse events (TRAEs).

ONCOLOGIST (2023)

添加到收藏夹

Article Medicine, General & Internal

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial

Tanios Bekaii-Saab, Takuji Okusaka, David Goldstein, Do-Youn Oh, Makoto Ueno, Tatsuya Ioka, Weijia Fang, Eric C. Anderson, Marcus S. Noel, Michele Reni, Hye Jin Choi, Jonathan S. Goldberg, Sang Cheul Oh, Chung-Pin Li, Josep Tabernero, Jian Li, Emma Foos, Cindy Oh, Eric Van Cutsem

Summary: In an open-label phase 3 study, it was found that the addition of napabucasin to nab-paclitaxel with gemcitabine did not improve efficacy in patients with previously untreated metastatic pancreatic adenocarcinoma (mPDAC). However, the safety profile of napabucasin was consistent with previous reports. This study reinforced the value of nab-paclitaxel plus gemcitabine as a platform for novel therapeutic approaches in mPDAC.

ECLINICALMEDICINE (2023)

添加到收藏夹

Article Oncology

Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma

Ilaria Trestini, Luisa Carbognin, Umberto Peretti, Isabella Sperduti, Alberto Caldart, Daniela Tregnago, Alice Avancini, Alessandra Auriemma, Giulia Orsi, Sara Pilotto, Luca Frulloni, Gabriele Capurso, Emilio Bria, Michele Reni, Giampaolo Tortora, Michele Milella

Summary: This retrospective study investigated the use of pancreatic enzyme replacement therapy (PERT) in advanced pancreatic ductal adenocarcinoma (PDAC) patients undergoing chemotherapy, and found that PERT was associated with significantly prolonged survival and alleviation of maldigestion-related symptoms.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Adjuvant nab-Paclitaxel plus Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open -Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni

Summary: In this randomized, open-label trial, adjuvant nab-paclitaxel + gemcitabine was compared with gemcitabine alone for resected pancreatic ductal adenocarcinoma. The study found that although nab-paclitaxel + gemcitabine showed favorable overall survival, it did not meet the primary endpoint of independently assessed disease-free survival.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-na & iuml;ve advanced pancreatic ductal adenocarcinoma

Zhou Zhu, Hui Tang, Jinrong Ying, Yuejuan Cheng, Xiang Wang, Yingyi Wang, Chunmei Bai

Summary: This study compared the efficacy and safety of S-1 with gemcitabine plus nab-paclitaxel (GS) versus gemcitabine plus nab-paclitaxel (GnP) as first-line chemotherapy for advanced pancreatic ductal adenocarcinoma (PDAC). The results showed that the GS regimen led to a significantly longer overall survival (OS) compared to the GnP regimen, while the progression-free survival (PFS), objective response rate (ORR), and incidence of severe adverse events were comparable between the GS and GnP groups.

CANCER BIOLOGY & MEDICINE (2023)

添加到收藏夹

Article Oncology

Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis

Konstantin Schlick, Antonia Gantschnigg, Alexander Seymer, Florian Huemer, Richard Greil, Lukas Weiss

Summary: This study compared the clinical efficacy of Gem-Nab and Gem-Ox in patients with pancreatic cancer and found no significant difference in survival rates and progression-free survival rates between the two regimens. Therefore, Gem-Ox can be considered as a potential first-line treatment option for inoperable advanced pancreatic cancer.

CANCER MEDICINE (2023)

添加到收藏夹

Article Oncology

FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study

Alberto Servetto, Antonio Santaniello, Fabiana Napolitano, Francesca Foschini, Roberta Marciano, Priscilla Cascetta, Anna Rita Amato, Maria Rosaria Augurio, Lucia Maresca, Pietro De Placido, Sabino De Placido, Luigi Formisano, Roberto Bianco

Summary: This study compared the clinical outcomes of first-line FOLFIRINOX and nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. The results showed that there were no significant differences in median progression-free survival and median overall survival between first-line FFN and NabGem. In patients receiving NabGem, second-line FFN may improve survival and progression-free survival.

FUTURE ONCOLOGY (2022)

添加到收藏夹

Article Oncology

hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma

Sheron Perera, Gun Ho Jang, Yifan Wang, Deirdre Kelly, Michael Allen, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, Mustapha Tehfe, Ravi Ramjeesingh, James Biagi, Bernard Lam, Julie Wilson, Sandra E. Fischer, George Zogopoulos, Faiyaz Notta, Steven Gallinger, Robert C. Grant, Jennifer J. Knox, Grainne M. O'Kane

Summary: In advanced PDAC, hENT1 mRNA expression predicts ORR and OS in patients receiving GnP, while no association was observed in patients receiving mFFX.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

Volker Kunzmann, Jens T. Siveke, Hana Alguel, Eray Goekkurt, Gabriele Siegler, Uwe Martens, Dirk Waldschmidt, Uwe Pelzer, Martin Fuchs, Frank Kullmann, Stefan Boeck, Thomas J. Ettrich, Swantje Held, Ralph Keller, Ingo Klein, Christoph-Thomas Germer, Hubert Stein, Helmut Friess, Marcus Bahra, Ralf Jakobs, Ingo Hartlapp, Volker Heinemann

Summary: The study compared the efficacy and safety of two multidrug induction chemotherapy regimens for locally advanced pancreatic cancer and found that nab-paclitaxel plus gemcitabine is similarly active and safe as nab-paclitaxel plus gemcitabine followed by FOLFIRINOX. However, further evidence is needed to determine whether this translates into improved overall survival for patients.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Article Oncology

Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study

Alberto Servetto, Antonio Santaniello, Fabiana Napolitano, Francesca Foschini, Roberta Marciano, Eleonora Mozzillo, Priscilla Cascetta, Anna Rita Amato, Maria Rosaria Augurio, Lucia Maresca, Pietro De Placido, Sabino De Placido, Luigi Formisano, Roberto Bianco

Summary: This retrospective analysis compared the effects of FFN and GemNab in treating locally advanced PDAC, showing that FFN had better overall survival outcomes and toxicity profiles compared to GemNab. More randomized controlled trials are needed to clarify the best treatment options for patients with locally advanced PDAC.

CANCERS (2021)

添加到收藏夹

Article Oncology

Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors

Clarisse Dromain, Marianne E. Pavel, Philippe Ruszniewski, Alison Langley, Christine Massien, Eric Baudin, Martyn E. Caplin

BMC CANCER (2019)

添加到收藏夹

Article Multidisciplinary Sciences

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

Monica Pascual-Garcia, Ester Bonfill-Teixidor, Ester Planas-Rigol, Carlota Rubio-Perez, Raffaella Ludaro, Alexandra Arias, Isabel Cuartas, Ada Sala-Hojman, Laura Escudero, Francisco Martinez-Ricarte, Isabel Huber-Ruano, Paolo Nuciforo, Leire Pedrosa, Carolina Marques, Irene Brana, Elena Garralda, Maria Vieito, Massimo Squatrito, Estela Pineda, Francesc Graus, Carmen EspejoH, Juan Sahuquillo, Josep Tabernero, Joan Seoane

NATURE COMMUNICATIONS (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls

Teresa Macarulla, Clara Montagut, Francisco Javier Sanchez-Martin, Monica Granja, Helena Verdaguer, Javier Sastre, Josep Tabernero

EXPERT OPINION ON BIOLOGICAL THERAPY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors

Lene Alifrangis, Rik Schoemaker, Niels J. Skartved, Rikke Hald, Clara Montagut, Scott Kopetz, Josep Tabernero, Michael Kragh, Janet R. Wade

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2020)

添加到收藏夹

Article Oncology

Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy Subgroup Analyses of a Randomized Clinical Trial

David H. Ilson, Josep Tabernero, Aliaksandr Prokharau, Hendrik-Tobias Arkenau, Michele Ghidini, Kazumasa Fujitani, Eric Van Cutsem, Peter Thuss-Patience, Giordano D. Beretta, Wasat Mansoor, Edvard Zhavrid, Maria Alsina, Ben George, Daniel Catenacci, Sandra McGuigan, Lukas Makris, Toshihiko Doi, Kohei Shitara

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer

Annalisa Lorenzato, Alessandro Magri, Vittoria Matafora, Valentina Audrito, Pamela Arcella, Luca Lazzari, Monica Montone, Simona Lamba, Silvia Deaglio, Salvatore Siena, Andrea Bertotti, Livio Trusolino, Angela Bachi, Federica Di Nicolantonio, Alberto Bardelli, Sabrina Arena

CANCERS (2020)

添加到收藏夹

Review Oncology

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers

Vito Amodio, Gianluca Mauri, Nicole M. Reilly, Andrea Sartore-Bianchi, Salvatore Siena, Alberto Bardelli, Giovanni Germano

Summary: A subset of colorectal cancers with mismatch repair deficiency are sensitive to immune checkpoint inhibitors, but some patients show primary resistance or develop acquired resistance. Changes in the Wnt and JAK-STAT signaling pathways, as well as alterations in the antigen presentation machinery, are associated with resistance to CPIs in these patients. Understanding the mechanistic basis of immune evasion in CRC provides rationale for innovative strategies to increase the subset of patients benefiting from CPIs.

CANCERS (2021)

添加到收藏夹

Article Oncology

Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases

Valentina Giannini, Laura Pusceddu, Arianna Defeudis, Giulia Nicoletti, Giovanni Cappello, Simone Mazzetti, Andrea Sartore-Bianchi, Salvatore Siena, Angelo Vanzulli, Francesco Rizzetto, Elisabetta Fenocchio, Luca Lazzari, Alberto Bardelli, Silvia Marsoni, Daniele Regge

Summary: This study validates a Δ-radiomics signature that can predict the response of individual colorectal cancer liver metastases (lmCRC) to oxaliplatin-based chemotherapy. The signature can reliably identify nonresponding lesions and potentially pave the way for lesion-specific therapies.

CANCERS (2022)

添加到收藏夹

Article Oncology

Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond

Maria Alsina, Josep Tabernero, Marc Diez

Summary: Gastric cancer is a global healthcare problem with multiple symptoms and fragility in patients. Multidisciplinary teams are required for palliative care and nutritional support. Sequential treatment is the best approach, and a third-line treatment can improve survival and quality of life.

CANCERS (2022)

添加到收藏夹

Article Oncology

GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells

Chiara Bellio, Marta Emperador, Pol Castellano, Albert Gris-Oliver, Francesc Canals, Alex Sanchez-Pla, Esther Zamora, Joaquin Arribas, Cristina Saura, Violeta Serra, Josep Tabernero, Bruce A. Littlefield, Josep Villanueva

Summary: Drug tolerant persister (DTP) cells enter a reversible slow-cycling state after treatment, with GDF15 identified as a key protein over-secreted and essential for their survival. Combining eribulin with an anti-GDF15 antibody may be effective in targeting and killing breast cancer DTP cells.

CANCERS (2022)

添加到收藏夹

Review Oncology

Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review

Gianluca Gazzaniga, Federica Villa, Federica Tosi, Elio Gregory Pizzutilo, Stefano Colla, Stefano D'Onghia, Giusy Di Sanza, Giulia Fornasier, Michele Gringeri, Maria Victoria Lucatelli, Giulia Mosini, Arianna Pani, Salvatore Siena, Francesco Scaglione, Andrea Sartore-Bianchi

Summary: This systematic review investigates the occurrence of pneumatosis intestinalis (PI) during oncological therapies, particularly in patients with respiratory system cancers and those treated with targeted therapies. PI mostly presents with mild to absent symptoms, but can lead to severe complications. Therefore, it is important to consider PI as a potential adverse event in oncological patients.

CANCERS (2022)

添加到收藏夹

Article Oncology

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study

Alessio Amatu, Gianluca Mauri, Federica Tosi, Katia Bencardino, Erica Bonazzina, Viviana Gori, Lorenzo Ruggieri, Sabrina Arena, Alberto Bardelli, Silvia Marsoni, Salvatore Siena, Andrea Sartore-Bianchi

Summary: Efficacy and safety of oxaliplatin-based regimens in late-care settings have been poorly reported. However, retreatment with oxaliplatin resulted in further response in around one-fifth of patients, but around one-third discontinued treatment due to adverse events. Translational studies to improve patient selection are warranted.

CANCERS (2022)

添加到收藏夹

Review Oncology

Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications

Nadia Saoudi Gonzalez, Francesc Salva, Javier Ros, Iosune Baraibar, Marta Rodriguez-Castells, Ariadna Garcia, Adriana Alcaraz, Sharela Vega, Sergio Bueno, Josep Tabernero, Elena Elez

Summary: Metastatic colorectal cancer is a complex and life-threatening disease influenced by various factors. Tumor heterogeneity, caused by genetic and non-genetic factors, affects tumor development and therapy effectiveness. Computational analysis of next-generation sequencing and real-time monitoring of circulating tumor DNA are valuable tools in understanding tumor evolution and heterogeneity.

CANCERS (2023)

添加到收藏夹

Editorial Material Oncology

Two-way traffic: aligning expectations with current realities in oncology. Mid-term ESMO Presidency considerations

Josep Tabernero

ESMO OPEN (2019)

添加到收藏夹

Meeting Abstract Oncology

Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic colorectal cancer: AGENT

J. Tabernero, G. Prager, S. Stintzing, H. J. Lenz, H. P. Nygren, C. Papadimitriou

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.